Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials

Keyphrases

• Liraglutide 100%
• Weight Management 100%
• Neuropsychiatric 100%
• Liraglutide 3.0 Mg 100%
• Placebo 66%
• Suicidal Ideation 66%
• Adverse Events 33%
• Adverse Event Reporting 33%
• Pooled Analysis 33%
• Mental Health 16%
• Body Mass Index 16%
• Suicidal Behavior 16%
• All-phase 16%
• Treatment Safety 16%
• Once-daily 16%
• Safety Data 16%
• Placebo Groups 16%
• Questionnaire Assessment 16%
• Mental Health Questionnaire 16%
• Randomized Double-blind Trial 16%
• Morbid Obesity 16%
• Patient Health Questionnaire-9 (PHQ-9) 16%
• Weight Management Program 16%
• Anti-obesity 16%
• GLP-1 Receptor Agonist 16%
• Columbia Suicide Severity Rating Scale 16%
• Treatment Imbalance 16%

Immunology and Microbiology

• Mental Health 100%
• Agonist 50%
• Body Mass 50%
• Comorbidity 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Liraglutide 100%
• Placebo 45%
• Adverse Event 36%
• Receptor 9%
• Glucagon Like Peptide 1 Receptor Agonist 9%
• Comorbidity 9%